bioRxivCancer Biology
NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4
P. Jain, A. Dvorkin-Gheva, E. Mollen, M. Xie, F. Jessa, P. Dhavarasa, S. Chung, K. R. Brown, G. H. Jang, F. Notta, J. Moffat, D. Hedley, P. C. Boutros, B. G. Wouters, M. Koritzinsky
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an almost universally fatal malignancy and there is an urgent need for new therapeutic targets. PDAC cells harbor genetic alterations and display metabolic changes that render them vulnerable to perturbations in redox homeostasis. Peroxiredoxin 4 (PRDX4) supports redox homeostasis by metabolizing H2O2 in the endoplasmic reticulum (ER). Based on functional genomics, we found that PDAC cell lines are dependent on PRDX4 for their growth and survival. We validated this dependency in established and primary PDAC cells, as well as 3D models and orthotopic xenografts. Cell death induced by PRDX4 depletion was accompanied by increased levels of reactive oxygen species (ROS), DNA damage and a DNA-PKcs-governed DNA damage response. As such, PRDX4 depletion also sensitized cells and tumors to ionizing radiation. The source of ROS that created a dependency on PRDX4 was attributed to NADPH oxidase 4 (NOX4), which localizes to the ER membrane. The functional requirement for PRDX4 was correlated with cellular NADPH levels across different models of PDAC and could be rescued by depletion of NOX4 or NADPH. As such, this study has identified NOX4 as a link between metabolic deregulation and ER-specific redox vulnerability in PDAC. Since PRDX4 is not an essential gene in normal tissues, our work also suggests that PRDX4 represents a novel therapeutic target for pancreatic cancer that may be particularly potent in combination with radiotherapy.
- organism: human
- assay: proteomics
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer
N. Abdel Hadi, G. Reyes-Castellanos, … A. Carrier·bioRxiv·Dec 28, 2022
- NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer
J. Doffo, S. A. Bamopoulos, … M. Wirth·bioRxiv·Oct 21, 2021
- Vertical RAS-pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations
Philipp Hafner, Steffen Johannes Keller, … Dietrich Alexander Ruess·Signal Transduction and Targeted TherapyPeer-reviewed·Jan 16, 2026
- Interactions with stromal cells promote a more oxidized cancer cell redox state in pancreatic tumors
R. Datta, A. N. Lau, … M. G. Vander Heiden·bioRxiv·Oct 20, 2020
- Stress adaptation pathways and HA-CD44 signaling maintain the survival of pancreatic cancer cells with centrosome amplification
Selahattin Can Özcan, Evrim Goksel, … Ceyda Açılan·Cell Communication and SignalingPeer-reviewed·Apr 7, 2026
- PI5P4Kα Regulates Iron Balance to Promote Metabolic Fitness in Pancreatic Cancer
Gurpreet K. Arora, Ryan M. Loughran, … Brooke M. Emerling·Cell ReportsPeer-reviewed·Aug 29, 2025